Latest news articles

Added 1 day ago Drug news

Positive interim results from phase III trial of tislelizumab in patients with first-line squamous NSCLC.- BeiGene

BeiGene, Ltd. announced that the pivotal Phase III trial evaluating its anti-PD-1 antibody tislelizumab in combination with two chemotherapy regimens...

Added 1 day ago Drug news

FDA grants priority review to GSK 2857916 in relapsed or refractory multiple myeloma.- GlaxoSmithKline

GlaxoSmithKline plc announced the FDA has granted a priority review for the company's Biologics License Application (BLA) seeking approval of...

Added 2 days ago Drug news

IDMC recommends early halt of phase III SANET-p study of HMPL 012 in neuroendocrine tumors – pancreatic.- Hutchison China MediTech

Hutchison China MediTech Limited announced that the independent Data Monitoring Committee of the Phase III pivotal study of HMPL 012...

Search all news articles for Oncology
 

 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars Knowledge Centre

Biosimilars Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

What's on the horizon?

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 2 years ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Marshall Pearce

Cancer immunotherapies

Posted 2 years ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Guidelines

Cannabis-based medicinal products

This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

Added 1 month ago

Biosimilars in the EU - Information guide for healthcare professionals

This guide has therefore been prepared with the important objective of providing healthcare professionals with reference information on both the science and regulation underpinning the use of biosimilars.

Added 2 days ago

End of life care for infants, children and young people with life-limiting conditions: planning and management

This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0–17 years) with life-limiting conditions. It aims to involve children, young people and their families...

Added 4 months ago

Search all guidelines for Oncology
 

Journal articles

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.

Introduction: To evaluate the possibility that switching from reference biologic medicines to biosimilars could lead to altered clinical outcomes, including enhanced immunogenicity, compromised safety, or diminished efficacy...

Added 2 days ago

Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.

Purpose of Review: Treatment goals and ambitions have even been upwardly revised since demonstration was made that under certain conditions, treatment-free remission was possible. Herein, we will discuss on how to try tailoring...

Added 9 days ago

The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML.

For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell field. In CML, the acquisition of the fusion...

Added 9 days ago

Search all journal articles for Oncology
 

Clinical trials

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.

Added 3 months ago

Trial of NanoPac Focal Therapy for Prostate Cancer

NanoPac is very small (submicron) particles of the chemotherapy drug, paclitaxel, which is administered intravenously in a number of types of cancer. These submicron particles are injected directly into solid tumors to target cancer at...

Added 13 days ago

A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy (STIMULUS-AML1)

This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination with hypomethylating agents (HMA) by evaluating MBG453 in combination with the HMA azacitidine and the Bcl-2 inhibitor venetoclax.

Added 2 months ago

Search all clinical trials for Oncology
 

Blog Posts

Advances in Precision Cancer Care

ESMO 2018 | Day 4 highlights

Posted 1 year ago

In our final report from ESMO 2018 we share insights from the Proffered paper session - Gastrointestinal tumours, colorectal, moderated by Dirk Arnold (Hamburg, DE) and Alfredo Falcone (Pisa, IT). Here, we cover survival data from the MODUL trial, comparing maintenance fluorouracil-bevacizumab and fluorouracil-bevacizumab plus atezolizumab in BRAF wild-type disease, and [in TRIBE2] consider the impact on PFS2 of an intensified treatment strategy versus a standard, sequential treatment strategy.

Advances in Precision Cancer Care

ESMO 2018 | Day 3 highlights

Posted 1 year ago

Sunday’s ESMO 2018 report comes from Presidential Symposium 2, moderated by Fortunato Ciardiello (Napoli, IT) and Josep Tabernero (Barcelona, ES). Here, we share key data and discussions from presentations on the STAMPEDE trial, looking at the role of prostate radiotherapy for patients with newly diagnosed metastatic prostate cancer and JAVELIN Renal 101, assessing avelumab plus axitinib as a first-line treatment option for patients with advanced renal cell carcinoma. 

Advances in Precision Cancer Care

ESMO 2018 | Day 2 highlights

Posted 1 year ago

Saturday’s ESMO 2018 report comes from Presidential Symposium 1, moderated by Andrés Cervantes (Valencia, ES) and Josep Tabernero (Barcelona, ES), discussing the scientific results and clinical implications of new data from the phase 3 IMpassion130, PALOMA-3 and SOLAR-1 trials. 

CME

Treatment Optimisation in Chronic Lymphocytic Leukaemia

Treatment Optimisation in Chronic Lymphocytic Leukaemia
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE

Managing the side effects of treatment for prostate cancer

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Personalisation of chronic lymphocytic leukaemia (CLL) care

Personalisation of chronic lymphocytic leukaemia (CLL) care
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE
Search all CME for Oncology